Pharma Industrial India Magazine - July - August 2024

PHARMA INDUSTRIALINDIA · JUL-AUG 24 23 ARTICLE inspections, complemented by advanced analytics to detect potential fraud, are essential. Furthermore, creating a global database of counterfeit incidents would enhance regulators’ and manufacturers’ ability to respond swiftly and effectively to new threats, facilitating real-time information sharing and coor- dinated efforts. The problem of counterfeit drugs is not just theoretical but a re- ality with significant implications. According to ASPA & CRISIL Report 2023 Survey revealed that about 25% of respondents willingly purchased counterfeit or duplicate pharmaceutical products due to the unavailability of original brands and lower costs. The prevalence of counterfeit pharmaceutical products is especially pronounced in non-metro cities, where the de- mand-supply gap exacerbates the issue. For instance, 29% of consumers in Indore, 32% in Hyderabad, 23% in Jalandhar, and 25% in Chennai reported encountering counterfeit phar- maceutical products. The supply of these counterfeit products is more prevalent in tier II/III cities and villages, where the pen- etration of organized pharmaceutical chains is limited due to lower access to healthcare services, a weak supply chain net- work, and high costs. Despite India being one of the largest manufacturers of generic medicines globally, the demand-sup- ply gap and low affordability often lead to a counterfeit or grey market, especially for medications targeting lifestyle diseases. Consumer education is another crucial aspect of the fight against counterfeit drugs. Organizations like the Authentica- tion Solutions Providers Association (ASPA) has contributed to this effort by organizing webinars, releasing brand awareness videos, and supporting initiatives like the GS1 India Healthcare Summit. As an industry, there is a responsibility to produce safe medications and empower consumers with the knowl- edge needed to protect themselves from dangerous counter- feit products. Educating the public about the risks associated with counterfeit drugs and providing them with tools to verify the authenticity of their medications is essential for creating a safer healthcare environment. The pharmaceutical industry must rise to the challenge of combating counterfeit drugs with a renewed commitment to innovation, collaboration, and transparency. This fight is not just about protecting market share; it is about saving lives and preserving trust in the medical system. By investing in cut- ting-edge technologies like blockchain and hologram seals, enhancing regulatory frameworks, and fostering greater indus- try collaboration, we can protect the integrity of our medicines and ensure a safer future for all. The battle against counterfeit medications presents an opportunity to redefine what it means to be a responsible, forward-thinking player in global health- care. The stakes are high, but our industry’s innovative spir- it must be applied to protect the medicines we produce and safeguard the health of patients worldwide.